162011-91-8

Upstream product

• 1778-09-2 4-(Methylthio)acetophenone 
• 10297-73-1 4-(methanesulfonyl)acetophenone 
• 2444-36-2 2'-chloro-benzeneacetic acid 
• 50413-24-6 2-bromo-1-(4-methanesulfonylphenyl)ethanone 
• 100-68-5 methyl-phenyl-thioether 

Downstream Products

• 1448458-95-4 (Z)-5-benzylidene-3-(2-chlorophenyl)-4-(4-(methylsulfonyl)phenyl)furan-2(5H)-one 
• 1448458-96-5 (Z)-5-(3-nitrobenzylidene)-3-(2-chlorophenyl)-4-(4-(methylsulfonyl)phenyl)furan-2(5H)-one 
• 1448458-97-6 (Z)-5-(2-methoxybenzylidene)-3-(2-chlorophenyl)-4-(4-(methylsulfonyl)phenyl)furan-2(5H)-one 
• 1448458-98-7 (Z)-5-(3,4,5-trimethoxybenzylidene)-3-(2-chlorophenyl)-4-(4-(methylsulfonyl)phenyl)furan-2(5H)-one 
• 1448458-99-8 (Z)-3-(2-chlorophenyl)-5-(furan-2-ylmethylene)-4-(4-(methylsulfonyl)phenyl)furan-2(5H)-one 
• 1448459-00-4 (Z)-5-(4-hydroxy-3-methoxybenzylidene)-3-(2-chlorophenyl)-4-(4-(methylsulfonyl)phenyl)furan-2(5H)-one 
• 1448459-01-5 (Z)-5-(4-hydroxybenzylidene)-3-(2-chlorophenyl)-4-(4-(methylsulfonyl)phenyl)furan-2(5H)-one 
• 1448459-02-6 (Z)-5-(4-bromobenzylidene)-3-(2-chlorophenyl)-4-(4-(methylsulfonyl)phenyl)furan-2(5H)-one 
• 1448459-03-7 (Z)-5-(4-chlorobenzylidene)-3-(2-chlorophenyl)-4-(4-(methylsulfonyl)phenyl)furan-2(5H)-one 
• 1448459-05-9 (Z)-5-(4-(dimethylamino)benzylidene)-3-(2-chlorophenyl)-4-(4-(methylsulfonyl)phenyl)furan-2(5H)-one 
• 1448459-07-1 (Z)-5-(4-methoxybenzylidene)-3-(2-chlorophenyl)-4-(4-(methylsulfonyl)phenyl)furan-2(5H)-one 
• 1448459-08-2 (Z)-3-(2-chlorophenyl)-4-(4-(methylsulfonyl)phenyl)-5-(naphthalen-1-ylmethylene)furan-2(5H)-one 
• 1448459-09-3 3-(2-chlorophenyl)-4-(4-(methylsulfonyl)phenyl)-5-(propan-2-ylidene)furan-2(5H)-one 
• 1448459-04-8 (Z)-5-(4-fluorobenzylidene)-3-(2-chlorophenyl)-4-(4-(methylsulfonyl)phenyl)furan-2(5H)-one 

Relevant academic research and scientific papers

Stereoselective synthesis and anti-proliferative effects on prostate cancer evaluation of 5-substituted-3,4-diphenylfuran-2-ones

Series of 5-substituted-3,4-diphenylfuran-2-ones were stereoselectively prepared. Their potential anti-proliferative effects on prostate cancer and some of their cyclooxygenases (COXs) inhibitory activities were evaluated. Structure-activity relationship (SAR) data, acquired by substituent modification at the para-position and ortho-position of the C-3 phenyl ring and 5-substituted modification of the central furanone, showed that 3-(2-chloro-phenyl)-4-(4-methanesulfonyl-phenyl)-5-(1-methoxy-ethyl) -5H-furan-2-one (13p) was the most potent compound and could effectively reduce the proliferation of prostate cancer cells (PC3 cell IC50 = 20 μM; PC3 PCDNA cell IC50 = 5 μM; PC3 SKP2 cell IC50 = 5 μM; DU145 cell IC50 = 25 μM). The cell cycle analysis for 13p in DU145 indicated that 13p may induce G1 phase arrest.

Phenyl heterocycles as cox-2 inhibitors

The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. STR1 The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.

Stilbene derivatives useful as cyclooxygenase-2 inhibitors

The invention encompasses novel compounds of Formula Iuseful in the treatment of cyclooxygenase-2 mediated diseases. STR1 The invention also encompasses certain pharmaceuticalcompositions and methods for treatment of cyclooxygenase-2 mediated diseases comprising the use of compounds of Formula I.

Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases

The present invention provides a method of treating a neurodegenerative disease and in particular Alzheimers disease which comprises administering to a human in need thereof a therapeutically effective amount of a non-steroid COX-II inhibitor. Although a wide range of COX-II inhibitors may be employed but it is preferred to employ compounds of the Formula I: STR1

Method of preventing bone loss

The invention encompasses a method of inhibiting bone resorption in patients in need of such inhibition to a degree sufficient to halt or retard loss of bone mass, reduce fractures, improve bone repair and prevent or treat osteoporosis comprising: the administration of a non-toxic therapeutically effective amount of a selective cyclooxygenase-2 inhibitor such as the compounds of formula I. STR1 The invention also encompasses certain pharmaceutical compositions for the purposes described above.

Phenyl heterocycles as cox-2 inhibitors

The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases, STR1 The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.